Open AccessCannabidiol and the Management of Pediatric Neurological Disorders: A Systematic Review
Author(s) -
Caio de Almeida Lellis,
Marco Alejandro Menacho Herbas,
João Cesar Pereira da Cunha,
Samyla Coutinho Paniago,
Paulo Sérgio Machado Diniz
Publication year - 2021
Language(s) - English
Resource type - Conference proceedings
DOI - 10.5327/1516-3180.266
Subject(s) - cannabidiol , medicine , pediatrics , dravet syndrome , randomized controlled trial , refractory (planetary science) , neurology , cannabis , medline , epilepsy , psychiatry , physics , astrobiology , political science , law
Due to an increase in cases of neurological disorders refractory to conventional treatments in pediatrics patients, other therapies have been sought. Objectives: To analyze the safety and efficacy of CBD in the management of neurological disorders in children. Design and setting: A systematic review conducted at the Pontifical Catholic University of Goiás. Methods: This is a systematic review carried out in PubMed, Lilacs and MedLine databases, with the descriptors: “(Pediatric OR Neurology) AND (Cannabidiol OR Cannabis)”, being selected only the randomized studies, meta-analysis and clinical trials published in the last 10 years. Results: One randomized trial concluded that daily oral CBD solution reduced the frequency of seizures in pediatric patients with Lennox-Gastaut syndrome (LGS). In addition, another study concluded that CBD (20 mg/kg/day) is associated with up to a 50% decrease in seizures in children with SLG and Dravet syndrome. Furthermore, it was pointed out that the association of oral CBD (2 to 5 mg/kg/day) with antiepileptic drugs caused a mean reduction of 36.5% of severe seizures. Finally, CBD enriched with 0.25% THC reduced spasticity, dystonia and pain intensity in children with complex motor disorder. Conclusion: CBD was shown to be safe and effective as a treatment for refractory epilepsies and complex motor disorder in pediatric patients, with no serious side effects reported.